11 completed. 11 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Completed 11 |
| Phase 2 | 4 | Completed 4 |
Follow Dosage Forms: new trials by email Literature Review of Dosage Forms trials Research Report on Dosage Forms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a) Naltrexone and Bupropion (NB) medication, Placebo - Loss-of-Control Eating, Obesity/Overweight | Phase 2 / Phase 3 | Completed | Yale University | 24 | 2022-06-10 | 2026-08-26 |
| Does IV Magnesium Improve Quality of Recovery With ERAS Protocols in Laparoscopic Colorectal Surgery? IV Medications, placebo - Colo-rectal Cancer, Anesthesia | Phase 3 | Completed | Thomas Jefferson University | 90 | 2022-05-27 | 2024-04-09 |
| Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b) Lisdexamfetamine Dimesylate (Medication), Placebo - Loss-of-control Eating, Obesity/Overweight | Phase 2 / Phase 3 | Completed | Yale University | 16 | 2022-01-02 | 2026-08-06 |
| EXHIT ENTRE Comparative Effectiveness Trial Extended Release Buprenorphine, Treatment as Usual - Substance Use Disorder, Opioid Use Disorder, Moderate | Phase 2 / Phase 3 | Completed | Gavin Bart | 344 | 2021-08-09 | 2025-12-09 |
| Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III) Vi-DT (Multi-dose formulation), Vi-DT (Single dose formulation), Control Vaccine - Typhoid | Phase 3 | Completed | International Vaccine Institute | 1800 | 2020-02-04 | 2021-08-27 |
| Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer Dronabinol in Oral Dosage Form, Placebo in Oral Dosage Form - Pancreatic Cancer Non-resectable, Chemotherapy-induced Nausea and Vomiting | Phase 3 | Completed | Arbeitsgemeinschaft medikamentoese Tumortherapie | 109 | 2019-12-16 | 2025-04-10 |
| Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care Bedaquiline Oral Tablet, Linezolid Oral Tablet, Delamanid in Oral Dosage Form - Tuberculosis, Pre-XDR-TB | Phase 3 | Completed | Wits Health Consortium (Pty) Ltd | 402 | 2019-08-22 | 2024-08-28 |
| A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation Paliperidone palmitate 3 month formulation (PP3M) - Schizophrenia | Phase 3 | Completed | Janssen-Cilag Ltd. | 306 | 2016-04-28 | 2025-04-27 |
| Adherence, Improvement Measure (AIM) System SMS medication adherence, No SMS adherence reminder - Patient Compliance, AIDS | Phase 3 | Completed | University of California, San Francisco | 99 | 2010-08-01 | 2013-11-20 |
| A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I) clofarabine (IV formulation), placebo, cytarabine - Acute Myelogenous Leukemia | Phase 3 | Completed | Genzyme, a Sanofi Company | 326 | 2006-08-01 | 2014-04-14 |
| Magnetic Brain Stimulation for the Treatment of Adult Depression Prefrontal rTMS, Antidepressant Regimen, Sham Stimulation - Depression | Phase 2 / Phase 3 | Completed | Medical University of South Carolina | 190 | 2005-02-01 | 2018-12-28 |
Obesity (2) · Overweight (2) · Acquired Immunodeficiency Syndrome (1) · Colonic Neoplasms (1) · Depression (1) · Extensively Drug-Resistant Tuberculosis (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Follicular (1) · Opioid-Related Disorders (1) · Pancreatic Neoplasms (1) · Patient Compliance (1) · Schizophrenia (1) · Substance-Related Disorders (1) · Tuberculosis (1) · Tuberculosis, Multidrug-Resistant (1)
Yale University (2) · Arbeitsgemeinschaft medikamentoese Tumortherapie (1) · Gavin Bart (1) · Genzyme, a Sanofi Company (1) · International Vaccine Institute (1) · Janssen-Cilag Ltd. (1) · Medical University of South Carolina (1) · Thomas Jefferson University (1) · University of California, San Francisco (1) · Wits Health Consortium (Pty) Ltd (1)
United States (7) · Germany (3) · France (2) · Austria (1) · Canada (1) · Croatia (1) · Denmark (1) · Greece (1) · Israel (1) · Italy (1) · Malaysia (1) · Netherlands (1) · Philippines (1) · Russia (1) · Saudi Arabia (1)
Carlos Grilo, PhD (1) · Felix Keil, Prof.MD (1) · Francesca M Conradie (1) · Gavin Bart, MD,PhD (1) · James Kahn, MD (1) · Josefina C Carlos, MD (1) · Mark S. George, MD (1) · Valentina Ivezaj, Ph.D. (1)
PMID 20439832, PMID 22585697, PMID 23769413, PMID 35186258, PMID 35664443, PMID 39623502, PMID 42341301
R01DK126637 (2), 1RC1MH088341 (1), 2008 (1), 2015 (1), 5UG1DA040316-05 (1), R01MH069887 (1)